Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3958781 | 1.00 | PRKACA (0.38) | PRKACAPRKACGPRKACBAMPD2NOTUM | |
| SCHEMBL7214657 | 0.87 | NOTUM (0.45) | NOTUMPOLBNPC1ALDH1A1HTT | |
| SCHEMBL3960711 | 0.81 | PRKACA (0.55) | PRKACAPRKACGPRKACBAMPD2NOTUM | |
| SCHEMBL3956712 | 0.81 | PRKACA (0.55) | PRKACAPRKACGPRKACBAMPD2NOTUM | |
| SCHEMBL14608536 | 0.76 | NOTUM (0.45) | AMPD2NOTUMPOLBNPC1ALDH1A1 | |
| SCHEMBL7220138 | 0.72 | NOTUM (0.43) | PRKACAPRKACGPRKACBNOTUMPOLB | |
| SCHEMBL3963409 | 0.70 | HTR7 (0.45) | — | |
| SCHEMBL13791446 | 0.69 | HTR1A (0.37) | ALDH1A1 | |
| SCHEMBL3956520 | 0.67 | NOTUM (0.59) | PRKACAPRKACGPRKACBAMPD2NOTUM | |
| SCHEMBL27718820 | 0.65 | GPR119 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544685-B2 | 2,3-dihydroindole compounds | H. LUNDBECK A/S (DK) | 2009-06-09 | — | — | US | disclosed |
| US-20070043058-A1 | Novel 2,3-dihydroindole compounds | H. LUNDBECK A/S (DK) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043058-A1 | Novel 2,3-dihydroindole compounds | HTR2C, HTR2A, HTR5A | PRKACA 4312/4885PRKACG 4552/4885PRKACB 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.